Stoke Therapeutics (STOK) Long-Term Investments (2024 - 2026)

Stoke Therapeutics has reported Long-Term Investments for 3 years, with the latest figure at $67.5 million in Q1 2026.

• For the quarter ending Q1 2026, Long-Term Investments rose 193.54% year-over-year to $67.5 million; the trailing twelve-month figure through Mar 2026 stood at $67.5 million (up 193.54% YoY), and the FY2025 full-year result was $106.3 million, up 256.29% from the prior year.
• Long-Term Investments for Q1 2026 stood at $67.5 million, down from $106.3 million in the prior quarter.
• The five-year high for Long-Term Investments was $107.3 million in Q2 2025, with the low at $23.0 million in Q1 2025.
• Average Long-Term Investments over 3 years is $63.4 million, with a median of $67.5 million recorded in 2026.
• Peak annual rise in Long-Term Investments reached 256.29% in 2025, while the deepest fall reached 168.15% in 2025.
• Tracing STOK's Long-Term Investments over 3 years: stood at $29.8 million in 2024, then soared by 256.29% to $106.3 million in 2025, then tumbled by 36.49% to $67.5 million in 2026.
• The last three Long-Term Investments figures came in at $67.5 million (Q1 2026), $106.3 million (Q4 2025), and $80.3 million (Q3 2025), per Business Quant data.

Peer Comparison